Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor ActivityJonathan D. Graves, Pamela M. Holland, Tammy L. Bush et al.|Cancer Cell|2014Cited by 155
AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing GlioblastomaKevin J. Hamblett, William C. Fanslow, Carl J. Kozlosky et al.|Molecular Cancer Therapeutics|2015Cited by 99